• Asian Pacific Journal of Cancer Prevention
• /
• 제15권5호
• /
• pp.2057-2060
• /
• 2014

Purpose: To assess the effect and safety of lobaplatin combinated floxuridine /pirarubicin in transcatheter hepatic arterial chemoembolization(TACE) of unresectable primary liver cancer. Patients and Methods: TACE combined with the chemotherapy regimen was used to treat 34 unresectable primary liver cancer patients. DSA/MRI/CT/blood routine examinations were used to evaluate short term activity and toxicity after 4-5 weeks, the process being repeated if necessary. Results: Among the 34 cases, 1 (2.9%) showed a complete response, 21 (61.7%) a partial response, 8 (23.5%) stable disease, and 4 progressive disease, with a total effective rate of 67.6%. The content of alpha fetoprotein dropped by over 50% in 20 cases (58.8%). The rate of recovery was hepatalgia (88.2%), ascites (47.1%), appetite (55.9%), Performance Status(30.4%). The median follow-up time (MFT) was 281 days (63-558 days), and median progression-free survival was 118.5 days (95%, CI:88.8-148.2days). Adverse reactions (III-IV grade) were not common, with only 4 cases of vomiting and 2 cases of thrombocytopenia (III grade). Conclusions: Lobaplatin-based TACE is an effective and safe treatment for primary liver cancer.

• Journal of Trauma and Injury
• /
• 제25권4호
• /
• pp.296-299
• /
• 2012

The aorta is the most common major thoracic artery injured by blunt chest trauma. Injuries to major aortic arch branch arteries can also occur but are much less common than aortic injuries in the setting of blunt trauma. Although internal mammary artery (IMA) injury is uncommon and rarely diagnosed in cases of blunt chest trauma, it is one of the important sources of bleeding in chest trauma. IMA bleeding can cause ongoing blood loss and may lead to serious conditions such as extensive hemothorax, anterior mediastinal hematoma or its catastrophic complication, cardiac tamponade. However such arotic and branch artery injuries are not easily detected by plain radiograph, and are detected indirectly because of associated mediastinal hematoma. Herein, we report a case of IMA injury caused by blunt chest trauma secondary to pedestrian traffic accident. The injured patient was successfully treated by transcatheter arterial embolization (TAE).

• 대한영상의학회지
• /
• 제84권6호
• /
• pp.1408-1413
• /
• 2023

외상성 부신 손상은 드물게 나타난다고 알려져 있으며, 최근 외상 환자에서 컴퓨터단층촬영 사용 빈도가 증가함에 따라 그 발견 빈도가 증가하고 있다. 그러나 손상의 희귀성, 임상적 표현과 예후의 다양성으로 인하여 부신 외상의 치료에 대한 명확한 지침은 형성되지 않았다. 본 증례 보고에서는 차량 사고로 인하여 재발성 우측 부신 출혈을 경험하였으며 이에 대하여 반복적인 경카테터 동맥 색전술을 이용하여 치료한 73세 남성 환자에 대하여 보고하고자 한다.

• Tuberculosis and Respiratory Diseases
• /
• 제42권1호
• /
• pp.50-57
• /
• 1995

연구배경: 기관지동맥 혹은 체측부동맥의 색전술은 수술전 환자상태의 안정화 혹은 지혈을 위해 또는 수술하기가 힘든 양측성 만성 폐질환환자에서 유용한 치료로 받아지고 있다. 이에 저자등은 객혈환자에서 동맥색전술의 효과와 색전술의 임상적, 방사선학적 특정과 환자의 경과 및 예후에 대하여 알아보고자 하였다. 방법: 1992년 4월부터 1993년 8월 까지 연세대학교 원주의과대학부속 원주기독병원에 객혈을 주소로 내원한 환자중 24시간 동안에 400cc이상의 대량객혈이나 내원시 2번이상의 반복적인 객혈로 동맥 색전술을 시행한 환자 58예를 대상으로 하였다. 결과: 환자들의 객혈의 원인 결핵이 34예(58%)로 가장 많았고 동맥 색전술시 시행한 혈관 조영상 과혈관신생과 기관지동맥과 폐동맥사이의 단락이 보이는 경우가 25예(43%)로 가장 많았다. 동맥 색전술은 Ivalon을 사용한 16예(27%), Gelform은 24예(41%), 두가지 모두 사용한 예는 17예(29%)였으며, 체측부동맥이 출혈에 관여한 경우가 32예(57%)였으며 동맥 색전술후 합병증은 모두 18예(31%)로 흉통이 6예, 발열 4예, 배뇨장애 4예로 비교적 경미한 합병증이 대부분(14예, 78%)이었다. 동맥 색전술후 재출혈은 15예(29%)였고 재출혈 환자군과 재출혈이 없었던 환자군의 비교에서 Gelform만 사용했던 환자가 의의있게 많았고, 원인 질환으로는 두 환자군사이에 의의있는 차이는 없었으며 혈관 조영술상에서는 체측부동맥이 재출혈군에서 의의있게 많았다. 결론: 객혈환자에서 특히 수술전에 지혈목적이나 폐기능 저하등의 이유로 수술을 할 수 없는 경우의 차선적 치료로 기관지 혹은 체측부동맥등의 동맥 색전술은 유용하고 안전한 방법이다. 또한 앞으로 장기적인 추적 관찰이 필요할것으로 생각된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권9호
• /
• pp.4757-4761
• /
• 2012

Objectives: To explore the impact of low- vs conventional-dose chemotherapy via transcatheter arterial chemo-embolization (TACE) on serum fibrosis indicators and treatment efficacy of hepatocellular cancer patients (HCC). Materials and Methods: Patients fulfilling the eligibility criteria were assigned to TACE in Group A (with low-dose chemotherapy) or Group B (conventional-dose chemotherapy). Four serum fibrosis related indicators, hyaluronic acid(HA), human pro-collagen type-III (hPC-III), laminin (LN), and collagen type-IV(IV-C) before TACE were compared with the values 7 days after TACE. The response rate and survival time were also compared between the two groups. Results: Fifty patients with HCC were enrolled in this study, including 25 in Group A and 25 in Group B. No significant differences were detected between the two groups in the four indicators before TACE. After TACE, the value of the four serum indicators increased significantly in Group B. However, no significant differences regarding these four indicators were found in Group A after TACE. Significant differences were demonstrated between the two groups after TACE, but median survival time and 1 or 2 year overall survival rates did not differ (P>0.05). Conclusions: Low-, compared with conventional-dose chemotherapy exerts the same impact on the variation of fibrosis related indicators and has no influence on median survival time and survival rate after TACE in HCC patients.

• 한국임상수의학회지
• /
• 제29권6호
• /
• pp.498-501
• /
• 2012

10개월의 수컷 말티즈견 (1.6 kg)이 간헐적인 기침과 지속성 심잡음을 주증으로 내원 하였다. 환축은 경흉부심초음파 검사와 혈관 조영검사를 통하여 좌우단락의 동맥관개존증 (PDA)으로 진단되었다. 혈관조영 검사를 통하여 동맥관의 형태 및 크기에 대해 평가한 뒤, 대퇴동맥으로 $Amplatz^{(R)}$ Canine Duct Occluder (ACDO) 장치를 삽입하는 투시 유도하 동맥관 폐쇄술이 시도되었다. 동맥관의 폐쇄직후 지속성 심잡음이 사라졌으며, 시술 후 실시된 혈관조영검사를 통하여 잔류혈류가 관찰되지 않았다. 투시 유도하에서 ACDO 장착 및 성공적인 동맥관의 완전폐쇄가 확인되었다. 환자는 시술 1일 뒤 퇴원하였으며, 임상증상 관찰 및 심장검사가 정기적으로 이루어 졌다. 시술 후 합병증은 발생하지 않았다. 결론적으로 본 증례의 경우 대퇴동맥내로 ACDO를 적용한 성공적인 동맥관개존증 폐쇄술에 대한 국내 첫 증례보고이다.

• Journal of Chest Surgery
• /
• 제50권4호
• /
• pp.255-262
• /
• 2017

Background: Transcatheter aortic valve replacement (TAVR) has been suggested as a less invasive treatment for high-risk patients with aortic valve disease. I n this study, we compared the outcomes of conventional surgical aortic valve replacement (AVR) and TAVR in elderly patients aged over 80. Methods: A total of 108 patients aged 80 years or older who underwent isolated AVR (n=35) or TAVR (n=73) from 2010 through 2015 at Asan Medical Center were identified. Early and late clinical outcomes, including echocardiographic findings, were evaluated in both groups. The mean follow-up duration was $766.4{\pm}528.7days$ in the AVR group and $755.2{\pm}546.6days$ in the TAVR group, and the average timing of the last follow-up echocardiography was at $492.6{\pm}512.5days$ in the AVR group and $515.7{\pm}526.8days$ in the TAVR group. Results: The overall early mortality was 2.8% (0 of 35, 0% in the AVR group vs. 3 of 73, 4.1% in the TAVR group). Permanent pacemaker insertion was significantly more common in the TAVR group (p=0.010). Renal failure requiring dialysis and new-onset atrial fibrillation was more frequent and the length of hospital stay was longer in the AVR group; however, this difference did not reach statistical significance. In the TAVR group, 14 patients (19.2%) were rehospitalized due to cardiac problems, and 13 patients (17.8%) had developed significant paravalvular leakage by the time of the last follow-up echocardiography. Conclusion: TAVR could be a good alternative to conventional surgical AVR in elderly patients. However, TAVR has several shortcomings, such as frequent significant paravalvular leakage or readmission, which should be considered in decision-making.

• Radiation Oncology Journal
• /
• 제32권1호
• /
• pp.14-22
• /
• 2014

Purpose: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) followed by radiotherapy (RT) in treatment-na$\ddot{i}$ve patients with locally advanced hepatocellular carcinoma (HCC). Materials and Methods: Eligibility criteria were as follows: newly diagnosed with HCC, the Barcelona Clinic Liver Cancer stage C, Child-Pugh class A or B, and no prior treatment for HCC. Patients with extrahepatic spread were excluded. A total of 59 patients were retrospectively enrolled. All patients were treated with TACE followed by RT. The time interval between TACE and RT was 2 weeks as per protocol. A median RT dose was 47.25 $Gy_{10}$ as the biologically effective dose using the ${\alpha}/{\beta}$ = 10 (range, 39 to 65.25 $Gy_{10}$). Results: At 1 month, complete response was obtained in 3 patients (5%), partial response in 27 patients (46%), stable disease in 13 patients (22%), and progressive disease in 16 patients (27%). The actuarial one- and two-year OS rates were 60.1% and 47.2%, respectively. The median OS was 17 months (95% confidence interval, 5.6 to 28.4 months). The median time to progression was 4 months (range, 1 to 35 months). Grade 3 or greater liver enzyme elevation occurred in only two patients (3%) after RT. Grade 3 gastroduodenal toxicity developed in two patients (3%). Conclusion: The combination treatment of TACE followed by RT with two-week interval was safe and it showed favorable outcomes in treatment-na$\ddot{i}$ve patients with locally advanced HCC. A prospective randomized trial is needed to validate these results.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권18호
• /
• pp.8665-8670
• /
• 2016

Background and Aims: Hepatitis B virus (HBV) reactivation was reported to be induced by transcatheter arterial chemoembolization (TACE) in HBV-related hepatocellular carcinonma (HCC) patients with a high incidence. The effective strategy to reduce hepatitis flares due to HBV reactivation in this specific group of patients was limited to lamivudine. This retrospective study was aimed to investigate the efficacy of prophylactic entecavir in HCC patients receiving TACE. Methods: A consecutive series of 191 HBV-related HCC patients receiving TACE were analyzed including 44 patients received prophylactic entecavir. Virologic events, defined as an increase in serum HBV DNA level to more than 1 log10 copies/ml higher than nadir the level, and hepatitis flares due to HBV reactivation were the main endpoints. Results: Patients with or without prophylactic were similar in host factors and the majorities of characteristics regarding to tumor factors, HBV status, liver function and LMR. Notably, cycles of TACE were parallel between the groups. Ten (22.7%) patients receiving prophylactic entecavir reached virologic response. The patients receiving prophylactic entecavir presented significantly reduced virologic events (6.8% vs 54.4%, p=0.000) and hepatitis flares due to HBV reactivation (0.0% vs 11.6%, p=0.039) compared with patients without prophylaxis. Kaplan-Meier analysis illustrated that the patients in the entecavir group presented significantly improved virologic events free survival (p=0.000) and hepatitis flare free survival (p=0.017). Female and Eastern Cooperative Oncology Group (ECOG) performance status 2 was the only significant predictors for virological events in patients without prophylactic antiviral. Rescue antiviral therapy did not reduce the incidence of hepatitis flares due to HBV reactivation. Conclusion: Prophylactic entecavir presented promising efficacy in HBV-related cancer patients receiving TACE. Lower performance status and female gender might be the predictors for HBV reactivation in these patients.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권12호
• /
• pp.6257-6261
• /
• 2012

Objective: To investigate the safety and efficacy of transcatheter arterial chemoembolization (TACE), combined with portal vein embolization (PVE), and high intensity focused ultrasound (HIFU) sequential therapy in treating patients with hepatocellular carcinoma (HCC). Methods: Patients with inoperative HCC were treated by two methods: in the study group with TACE first, then PVE a week later, and then TACE+PVE every two months as a cycle, after 2~3 cycles finally HIFU was given; in the control group only TACE+PVE was given. Response (CR+PR), and disease control rate (CR+PR+SD), side effects, overall survival and time to progress were calculated. Results: Main side effects of both groups were nausea and vomiting. No treatment related death occurred. In the study group, 32 patients received TACE for overall 67 times, PVE 64 times, and HIFU 99 times; on average 2.1, 2 and 3.1 times for each patient, respectively. In the control group, 36 patients were given TACE 78 times and PVE 74 times, averaging 2.2 and 2.1 times per patient. Effective rate: 25.0% in study group and 8.3% in control group (p>0.05). Disease control rates were 71.9% and 44.4%, respectively (p<0.05). In patients with portal vein tumor thrombus, the rate reduced over 1/2 after treatment was 69.2%(9/13) in the study and 21.4%(3/14) in the control group (p<0.05). Rate of AFP reversion or decrease over 1/2 was 66.7%(16/24) in study and 37%(10/27) (p<0.05) in control group. Median survival time: 16 months in study and 10 months in control group. PFS was 7months in study and 3 months in control group. Log-rank test suggested that statistically significant difference exists between two groups (p=0.024). 1-, 2- and 3-year survival rates were 56.3%, 18.8% and 9.3% in study, while 30.6%, 5.6% and 0 in control group, respectively, with statistically significant difference between two groups (by Log-rank, p = 0.014). Conclusions: The treatment of TACE+PVE+HIFU sequential therapy for HCC increases response rate, prolong survival, and could thus be a safe and effective treatment for advanced cases.